Original Article
Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction
N Engl J Med 1998; 339:489-497August 20, 1998
- Abstract
Background
Long-term administration of beta-adrenergic blockers to patients after myocardial infarction improves survival. However, physicians are reluctant to administer beta-blockers to many patients, such as older patients and those with chronic pulmonary disease, left ventricular dysfunction, or non–Q-wave myocardial infarction.
Methods
The medical records of 201,752 patients with myocardial infarction were abstracted by the Cooperative Cardiovascular Project, which was sponsored by the Health Care Financing Administration. Using a Cox proportional-hazards model that accounted for multiple factors that might influence survival, we compared mortality among patients treated with beta-blockers with mortality among untreated patients during the two years after myocardial infarction.
Results
A total of 34 percent of the patients received beta-blockers. The percentage was lower among the very elderly, blacks, and patients with the lowest ejection fractions, heart failure, chronic obstructive pulmonary disease, elevated serum creatinine concentrations, or type 1 diabetes mellitus. Nevertheless, mortality was lower in every subgroup of patients treated with beta-blockade than in untreated patients. In patients with myocardial infarction and no other complications, treatment with beta-blockers was associated with a 40 percent reduction in mortality. Mortality was also reduced by 40 percent in patients with non–Q-wave infarction and those with chronic obstructive pulmonary disease. Blacks, patients 80 years old or older, and those with a left ventricular ejection fraction below 20 percent, serum creatinine concentration greater than 1.4 mg per deciliter (124 μmol per liter), or diabetes mellitus had a lower percentage reduction in mortality. Given, however, the higher mortality rates in these subgroups, the absolute reduction in mortality was similar to or greater than that among patients with no specific risk factors.
Conclusions
After myocardial infarction, patients with conditions that are often considered contraindications to beta-blockade (such as heart failure, pulmonary disease, and older age) and those with nontransmural infarction benefit from beta-blocker therapy.
Media in This Article
Figure 3
Adjusted Probability of Survival According to Age among Patients Who Received or Did Not Receive Beta-Blockers.Figure 2
Adjusted Probability of Survival among Patients with or without a History of Chronic Obstructive Pulmonary Disease (COPD) Who Received or Did Not Receive Beta-Blockers.Article Activity
- Article
Several large trials have demonstrated that the long-term administration of beta-adrenergic blockers to patients after myocardial infarction improves survival.1-3 Although the percentage of such patients receiving beta-blockade has recently increased, physicians still reportedly prescribe beta-blockers for less than one third,4 and cardiologists for less than half,5 of patients with myocardial infarction. Older age, impaired left ventricular function, transient heart failure, and the use of diuretic drugs predict lack of use of these drugs.6 This suggests that physicians are concerned that beta-blockers may be contraindicated in a substantial proportion of patients.
The Cooperative Cardiovascular Project, a program to evaluate the care of Medicare patients with a diagnosis of myocardial infarction, provides the opportunity to evaluate the relation between treatment and outcome in unselected patients, most of whom are over 65 years of age. With more than 200,000 charts abstracted, this data base gives investigators the power to evaluate the effect of interventions in situations rarely studied before. Moreover, this data base provides information on unselected patients with conditions that often keep them out of randomized, controlled trials.
We sought to use the Cooperative Cardiovascular Project data to determine which patients benefit from the use of beta-blockers. We compared the mortality rates of patients in high- and low-risk subgroups who were treated with beta-blockers with the rates among those not given those drugs. Correcting to the extent possible for differences between the groups, we evaluated the effects of beta-blockers in patients with presumed contraindications to their use, such as older age, low ejection fraction, chronic obstructive pulmonary disease, diabetes mellitus, low blood pressure, and low heart rate. In addition, the data base provided the opportunity to look at beta-blockade in the setting of contemporary medical practice.
Methods
The Cooperative Cardiovascular Project data base includes all acute care hospital claims for patients with a principal diagnosis of acute myocardial infarction that were submitted to the Health Care Financing Administration for Medicare payment. A diagnosis of acute myocardial infarction was defined according to the coding system of the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), as code 410, with those with a fifth digit of 2 (for episode of care), those reported by nonacute care hospitals, and those with missing medical-record numbers excluded. The national sample consisted of all discharges involving cases of acute myocardial infarction during an eight-month period, with data from the various states collected so that most discharges fell between February 1994 and July 1995.
The total number of discharges in the national sample was 201,752. The abstraction was performed by trained medical abstractors using uniform criteria to define each data item. They had access to all original hospital records. Extensive quality-control measures were applied to validate the reliability and accuracy of the abstracts. Finally, extensive checks were run against the computerized abstracts to ensure internal consistency and to enforce common data standards.7
The data were nearly complete. Serum creatinine concentrations were missing for 9575 patients, and most other data were missing for even fewer patients. The ejection fraction was obtained or documented in 134,238 patients. Patients for whom the ejection fraction was missing were analyzed as a separate subgroup. To avoid eliminating the few patients who had other missing data from the analyses, we combined patients with missing data into the largest group for all variables other than the one being analyzed.
Whenever possible, the data reflect the values obtained on admission to the hospital. The Health Care Financing Administration's survival data were based on Social Security records and were complete, with accuracy of 98 to 99 percent, at 60 days.
In this study, the Cooperative Cardiovascular Project data were used to address the question of who benefits from beta-blocker therapy. Initially, the patients prescribed and not prescribed beta-blocker therapy were compared with regard to a number of demographic and clinical variables. Patients for whom any beta-blocker at any dose had been prescribed at the time of discharge were classified as having received a beta-blocker. The means and standard deviations of continuous variables were compared. Both continuous (in categories) and discrete variables were compared with contingency-table analyses.
Comparison of mortality rates between patients receiving and those not receiving beta-blocker therapy was based on a time-to-event analysis. The Cox proportional-hazards model was used for this purpose, because it permitted estimated survival time to be controlled for differences in follow-up time and differences in covariates that might affect survival, including both confounding variables and effect modifiers. The proportional-hazards assumption was initially checked with Kaplan–Meier analyses and was found to be adequately met. Only 8464 of the total of 201,752 patients were not followed for 24 months.
Because of the size of the data set, emphasis was placed on the magnitude rather than the statistical significance of differences between groups. We recognized that very small differences could (and did) achieve statistical significance.
Results
Thirty-four percent of the patients received beta-blockers (Table 1Table 1
Characteristics of Patients Who Received or Did Not Receive Beta-Blockers at Hospital Discharge.). The percentage was lower among the very elderly, blacks, and those patients considered the sickest according to their Acute Physiology and Chronic Health Evaluation (APACHE II)8 and Killip9 scores. Similarly, patients with the lowest ejection fractions, heart failure, chronic obstructive pulmonary disease, elevated serum creatinine concentrations, or type 1 diabetes mellitus were less likely to be treated with beta-blockade. Conversely, patients who had been given more aggressive treatment, including thrombolysis and angioplasty, but not bypass surgery, were more likely to be receiving beta-blockers.As a result of these prescribing practices, patients receiving beta-blockers tended to have fewer risk factors for mortality than those not receiving beta-blockers. They were younger (mean [±SD] age, 73.3±8.8 vs. 74.5±9.0 years) and had lower (i.e., more favorable) APACHE II scores (7.9±3.4 vs. 9.0±4.4) and lower Killip scores. Their hospital stay was shorter (7.2±5.1 vs. 7.8±7.5 days), and their physiologic condition, as indicated by the serum creatinine concentration (1.3±1.0 vs. 1.4±1.1 mg per deciliter [115±88 vs. 124±97 μmol per liter]) and left ventricular ejection fraction (47±13 percent vs. 44±14 percent), was better. They had fewer coexisting diseases, including chronic obstructive pulmonary disease, diabetes, and congestive heart failure. Finally, they were more likely to be given thrombolytic and reperfusion therapy. The only exceptions to the favorable profile among those prescribed beta-blockers were the slightly higher proportions of patients with hypertension and of men in this group.
Because of the better risk-factor profile among those treated with beta-blockers, it was necessary to hold each risk factor constant when comparing mortality among those treated and those not treated with beta-blockers. Each of the subsequent analyses took direct account of or held constant the following factors: age; race or ethnic group; sex; APACHE II score; length of hospital stay; Killip score; physiologic condition at admission, as reflected by the systolic blood pressure, pulse rate, and serum creatinine concentration; left ventricular ejection fraction; presence or absence of coexisting diseases, including diabetes, congestive heart failure, chronic obstructive pulmonary disease, and asthma; type of myocardial infarction (anterior, inferior, or non–Q-wave); history of myocardial infarction, revascularization, or heart failure; and treatment, including aspirin, angiotensin-converting–enzyme inhibitors, calcium-channel blockers, heparin, thrombolytic agents, coronary angioplasty, and bypass surgery.
Table 2Table 2
Adjusted Risk and Relative Risk of Death among Patients Who Received or Did Not Receive Beta-Blockers at Hospital Discharge. shows the 24-month adjusted risks and relative risks of death among patients prescribed beta-blockers and those not prescribed the drugs. After demographic and physiologic measures and coexisting diseases were accounted for, patients treated with beta-blockade had substantially lower mortality in every subgroup. Among patients with myocardial infarction and no other complications, treatment with beta-blockers was associated with a 40 percent reduction in mortality during the follow-up period. Mortality was also reduced by 40 percent among patients with non–Q-wave infarction (Figure 1Figure 1
Adjusted Probability of Survival among Patients with Q-Wave and Non–Q-Wave Myocardial Infarction (MI) Who Received or Did Not Receive Beta-Blockers.) and patients with chronic obstructive pulmonary disease (Figure 2Figure 2Adjusted Probability of Survival among Patients with or without a History of Chronic Obstructive Pulmonary Disease (COPD) Who Received or Did Not Receive Beta-Blockers.). However, the reduction in mortality among those treated with beta-blockers was smaller among black patients (28 percent). Older patients (Figure 3Figure 3Adjusted Probability of Survival According to Age among Patients Who Received or Did Not Receive Beta-Blockers.) and those with a left ventricular ejection fraction below 20 percent (Figure 4Figure 4
Adjusted Probability of Survival According to Left Ventricular Ejection Fraction among Patients Who Received or Did Not Receive Beta-Blockers.), a serum creatinine concentration higher than 1.4 mg per deciliter, or diabetes mellitus also had a smaller percentage reduction in mortality. However, because of the higher mortality rates in these subgroups, the use of beta-blockers actually resulted in an absolute reduction in mortality similar to or greater than that in patients with no specific risk factors.Discussion
Patients who received beta-blockers had a 40 percent lower mortality rate than those who did not have beta-blockers prescribed at the time of discharge from the hospital. This reduction was even greater than the 22 percent reduction found in a meta-analysis of 23 trials.10 Furthermore, all subgroups of patients had similar reductions in mortality in the present study.
Nonetheless, only 34 percent of patients were discharged with a prescription for beta-blockers. Low-risk patients were more likely to be treated with beta-blockade, but nevertheless only 41 percent of patients with normal ejection fractions received beta-blockers. This finding is consistent with the results of previous studies that have shown low rates of use of beta blockers for young, “ideal” candidates.5 The most severely ill patients were even less likely to receive beta-blockers. If one assumes a mean reduction of 9.5 deaths per 100 patients with myocardial infarction in 24 months, more than 19,000 patients could have been kept alive had beta-blockers been more widely prescribed.
Non–Q-Wave Infarction
The relative risk of death in patients with non–Q-wave infarction who were prescribed beta-blockers was markedly decreased. This is important, because the use of beta-blockers in such patients has been questioned since the β-Blocker Heart Attack Trial found no improvement in survival among patients with nontransmural infarction who were given beta-blockers.11 However, this study was a subgroup analysis performed at a time when the treatment of non–Q-wave infarction was substantially different from present practice. Indeed, the American College of Cardiology and American Heart Association joint guidelines for the management of acute myocardial infarction classify the evidence for the use of beta-blockade in this subgroup as conflicting and possibly unfavorable.12 The overwhelming evidence from our study, however, suggests that beta-blockade should be part of the treatment of patients with non–Q-wave infarction.
Older Age
The present study demonstrates that older patients have a greater absolute benefit when treated with beta-blockade. Indeed, even among those 80 years of age or older, mortality was 32 percent lower when beta-blockers were prescribed. It is thus unfortunate that the elderly often receive less treatment after a myocardial infarction than younger patients.13 The present study found that only 27 percent of those over 84 years of age received beta-blockers. In a previous study of elderly patients admitted to a nursing home with evidence of a prior myocardial infarction, only 8 percent were receiving beta-blockade. Interestingly, in that study 37 percent of the patients were receiving calcium-channel blockers, which have not been shown to improve survival and may actually increase mortality.14
There are few studies of older patients, which might explain the reluctance on the part of many physicians to use these agents. Previous studies, even of elderly patients, have generally limited analysis to patients less than 69 or 75 years of age.15 Nevertheless, the results of our study are consistent with those of an analysis of 5332 Medicare patients without relative contraindications to beta-blockade.16
Diabetes Mellitus
Diabetic patients treated with beta-blockers had a 36 percent reduction in mortality. The present study supports previous work demonstrating that patients with diabetes have a worse outcome after myocardial infarction than those without diabetes.17,18 However, physicians have been reluctant to treat diabetic patients with beta-blockers because of the risk of worsening the diabetes or of masking hypoglycemic symptoms. Although it is true that blood glucose concentrations may increase with the use of some beta-blockers,19 our study confirms previous studies that have documented the benefit of beta-blockade in patients with diabetes mellitus.20,21 Because of the high mortality rate among diabetic patients after myocardial infarction, the absolute survival benefit is particularly large in this group of patients.
Pulmonary Disease
Patients with a history of chronic obstructive pulmonary disease had a high mortality rate but had a risk reduction of 40 percent with beta-blockade. Even patients with a history of asthma had lower mortality with beta-blockers, although these might be the patients under observation who tolerated the drug.
Many physicians withhold beta-blockers from patients with pulmonary disease because of concern about bronchoconstriction. It is true that beta-blockers cause bronchoconstriction in patients with asthma,22 and bronchial hyperresponsiveness has even been reported in patients with chronic obstructive pulmonary disease.23 Indeed, such patients have generally not been evaluated in studies of beta-blockers because of concern about bronchial hyperresponsiveness. However, the stimuli to hyperresponsiveness in patients with chronic obstructive pulmonary disease may be different from those in patients with asthma, and beta-blockade may not cause bronchoconstriction in patients with chronic obstructive pulmonary disease.23 This may be the reason that in a study of 50 patients with chronic obstructive pulmonary disease who were given esmolol, there was no change in pulmonary function.24
It appears clear that beta-blockers should be tried in patients with chronic obstructive pulmonary disease who have had myocardial infarction. It may be necessary in a very few patients to discontinue the drug because of bronchoconstriction, but the potential benefit appears large enough to warrant this small risk. We did not compare β1-selective and nonselective drugs. It is possible that they may have different effects on mortality because β1-selective drugs have less pulmonary effect.25
Congestive Heart Failure
Whether beta-blockers should be given to patients with both congestive heart failure and myocardial infarction remains controversial. Despite initial concern that the negative inotropic effects of beta-blockade would be detrimental in patients with heart failure, recent studies have suggested that the long-term effects of beta-blockade are beneficial.26-28 However, patients with ischemic cardiomyopathy may not fare as well,29 and many studies of heart failure have evaluated patients with nonischemic cardiomyopathy.
There are no randomized studies evaluating the effects of beta-blockers in patients with recent myocardial infarction and poor cardiac function. In one retrospective analysis, propranolol was effective in patients with a history of congestive heart failure,30 but the sickest patients have traditionally been excluded from studies.
The present analysis suggests that patients with the poorest cardiac function benefit as much as patients with better function. Patients with congestive heart failure had a 40 percent reduction in mortality when they received beta-blockers. The relative risk of death decreased by 40 percent in patients with an ejection fraction between 20 percent and 49 percent and by 32 percent in patients with an ejection fraction below 20 percent. However, since patients with the lowest ejection fractions have the highest mortality rate, the absolute benefit for these patients is actually greater than for those with higher ejection fractions. The estimates of ejection fraction are obtained by various methods and should not be considered precise. They do show, however, that patients can benefit from beta-blockade regardless of their ejection fraction.
Low-Risk Patients
The risks of a drug could conceivably be greater than the benefits in relatively healthy patients. Indeed, the recommendations of the American Heart Association for the treatment of myocardial infarction state that “there is continued debate about whether low-risk subjects . . . should be treated with β-adrenoceptor blockers because their long-term prognosis is extremely favorable irrespective of such therapy.”12 In the present study, however, the lowest-risk subgroups had a decrease in mortality of 40 percent with beta-blockade. These subgroups included patients with normal ejection fractions, patients with low serum creatinine concentrations, and those who had undergone revascularization or thrombolysis.
Randomized studies of beta-blocker therapy were performed in the prethrombolytic era, raising the question of whether beta-blockers are beneficial in patients who have undergone reperfusion.31 Previous smaller analyses of patients receiving thrombolytic agents have not clearly shown a long-term effect on mortality. For example, immediate use of beta-blockers did not improve long-term survival in the II-B substudy of the Thrombolysis in Myocardial Infarction trial.32 We found a decrease in mortality of 40 percent with the use of beta-blockers in this low-risk subgroup.
Because of their lower mortality rates, the absolute benefit is not as great in members of low-risk subgroups, but beta-blockers substantially improved survival in these patients. The question posed by the American College of Cardiology and American Heart Association guidelines for the treatment of patients with acute myocardial infarction appears to have been answered, at least with respect to the predominantly elderly patients analyzed in the present study.
Race
Black patients with hypertension do not respond as well as whites to treatment with beta-adrenergic blockers.33,34 The reasons are unknown, but they may be related to differences in beta-adrenoceptor sensitivity.35 This difference has aroused concern that blacks may not benefit from beta-blockade after myocardial infarction. In contrast to the β-Blocker Heart Attack Trial, which found similar benefits in whites and blacks,36 the benefit in blacks appeared to be lower in the present study. This could be due to differences in the sympathetic nervous system, differences in the use of the drugs, or other factors. Nevertheless, it should be noted that both blacks and whites had decreased mortality rates when given beta-blockers.
Limitations
Our study was not a randomized, controlled trial, and its conclusions must be viewed with important reservations. We could not control for characteristics that may influence a physician's decision to prescribe beta-blockers or the patient's decision to comply with a physician's choice of therapy. It is possible that patients who received beta-blockers were healthier than patients who did not or that they differed in some other way that caused them to have lower mortality. They could have had better physicians or have received different medications after discharge. Nevertheless, we attempted to control for or study the interactive effects of most of the known risk factors.
It is also possible that there were a substantial number of crossovers between the groups. The data reflect beta-blocker use at hospital discharge; some patients may have started treatment later, and some may have discontinued it. Such an effect, however, would be expected to decrease the power of the study.
The consistency among groups suggests that the results of the present analysis reflect the benefit of the intervention. The present analysis also confirms previous studies, but it extends the evidence of the benefit of beta-blockade to groups not previously evaluated. In contrast to other studies, however, our analysis of a large number of patients did not exclude patients at highest risk.
This analysis strongly indicates that beta-blockade is an underused therapy for patients who have had a myocardial infarction. Despite a decrease in mortality of between 28 and 40 percent, patients in many subgroups are not being prescribed these drugs. In addition to otherwise healthy patients, those with nontransmural infarction, heart failure, pulmonary disease, and older age are likely to benefit when given beta-blockers after a myocardial infarction.
Supported by a grant from the Delmarva Foundation for Medical Care and by the Health Care Financing Administration.
We are indebted to Thomas Marciniak, M.D., and William Oetgen, M.D., for their help and support.
Source Information
From the Department of Medicine and the Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore.
Address reprint requests to Dr. Gottlieb at the Division of Cardiology, University of Maryland Medical Systems, 22 S. Greene St., Baltimore, MD 21201.
- References
References
1
(beta)-Blocker Heart Attack Study Group
CrossRef | Web of Science2
The Norwegian Multicenter Study Group
Full Text | Web of Science | Medline3
Hjalmarson A ,Elmfeldt D ,Herlitz J , et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981;2:823-827
CrossRef | Web of Science | Medline4
Ellerbeck EF ,Jencks SF ,Radford MJ , et al. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-1514
CrossRef | Web of Science | Medline5
Brand DA ,Newcomer LN ,Freiburger A ,Tian H . Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995;26:1432-1436
CrossRef | Web of Science | Medline6
Viskin S ,Kitzis I ,Lev E , et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995;25:1327-1332
CrossRef | Web of Science | Medline7
Marciniak TA ,Ellerbeck EF ,Radford MJ , et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998;279:1351-1357
CrossRef | Web of Science | Medline8
Knaus WA ,Draper EA ,Wagner DP ,Zimmerman JE . APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829
CrossRef | Web of Science | Medline9
Killip T III ,Kimball JT . Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 1967;20:457-464
CrossRef | Web of Science | Medline10
Yusuf S ,Wittes J ,Friedman L . Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988;260:2088-2093
CrossRef | Web of Science | Medline11
(beta)-Blocker Heart Attack Study Group
CrossRef | Web of Science12
Committee on Management of Acute Myocardial Infarction
CrossRef | Web of Science | Medline13
Anderson JL . Medical therapy for elderly patients who have had myocardial infarction: too little to the late in life? Ann Intern Med 1996;124:335-338
Web of Science | Medline14
Aronow WS . Prevalence of use of beta blockers and of calcium channel blockers in older patients with prior myocardial infarction at the time of admission to a nursing home. J Am Geriatr Soc 1996;44:1075-1077
Web of Science | Medline15
Gundersen T ,Abrahamsen AM ,Kjekshus J ,Ronnevik PK . Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation 1982;66:1179-1184
CrossRef | Web of Science | Medline16
Soumerai SB ,McLaughlin TJ ,Spiegelman D ,Hertzmark E ,Thibault G ,Goldman L . Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-121
CrossRef | Web of Science | Medline17
Zuanetti G ,Latini R ,Maggioni AP ,Santoro L ,Franzosi MG . Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993;22:1788-1794
CrossRef | Web of Science | Medline18
Kjekshus J ,Gilpin E ,Cali G ,Blackey AR ,Henning H ,Ross J Jr . Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43-50
Web of Science | Medline19
Giugliano D ,Acampora R ,Marfella R , et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997;126:955-959
Web of Science | Medline20
Gundersen T ,Kjekshus J . Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285-290
CrossRef | Web of Science | Medline21
Malmberg K ,Herlitz J ,Hjalmarson A ,Ryden L . Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction: retrospective data from two large studies. Eur Heart J 1989;10:423-428
Web of Science | Medline22
Tattersfield AE . Respiratory function in the elderly and the effects of beta blockade. Cardiovasc Drugs Ther 1991;4:Suppl 6:1229-1232
CrossRef | Medline23
Woolcock AJ ,Anderson SD ,Peat JK , et al. Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma. Am Rev Respir Dis 1991;143:1438-1443
Web of Science | Medline24
Gold MR ,Dec GW ,Cocca-Spofford D ,Thompson BT . Esmolol and ventilatory function in cardiac patients with COPD. Chest 1991;100:1215-1218
CrossRef | Web of Science | Medline25
Fogari R ,Zoppi A ,Tettamanti F ,Poletti L ,Rizzardi G ,Fiocchi G . Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990;4:1145-1149
CrossRef | Web of Science | Medline26
Packer M ,Bristow MR ,Cohn JN , et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N EnglJ Med 1996;334:1349-1355
Full Text | Web of Science | Medline27
Waagstein F ,Bristow MR ,Swedberg K , et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446
CrossRef | Web of Science | Medline28
CIBIS Investigators and Committees
Web of Science | Medline29
Woodley SL ,Gilbert EM ,Anderson JL , et al. β-Blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441
Web of Science | Medline30
Chadda K ,Goldstein S ,Byington R ,Curb JD . Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510
CrossRef | Web of Science | Medline31
Becker RC . Beta-adrenergic blockade following thrombolytic therapy: is it helpful or harmful? Clin Cardiol 1994;17:171-174
CrossRef | Web of Science | Medline32
Roberts R ,Rogers WJ ,Mueller HS , et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991;83:422-437
Web of Science | Medline33
Materson BJ ,Reda DJ ,Cushman WC , et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-921[Erratum, N Engl J Med 1994;330:1689.]
Full Text | Web of Science | Medline34
Prisant LM ,Mensah GA . Use of beta-adrenergic receptor blockers in blacks. J Clin Pharmacol 1996;36:867-873
Web of Science | Medline35
Johnson JA ,Burlew BS ,Stiles RN . Racial differences in beta-adrenoceptor-mediated responsiveness. J Cardiovasc Pharmacol 1995;25:90-96
CrossRef | Web of Science | Medline36
Haywood LJ . Coronary heart disease mortality/morbidity and risk in blacks. I. Clinical manifestations and diagnostic criteria: the experience with the Beta Blocker Heart Attack Trial. Am Heart J 1984;108:787-793
CrossRef | Web of Science | Medline
- Citing Articles (247)
Citing Articles
1
Christian Jons, Poul Erik Bloch Thomsen. (2011) Treating Cardiac Arrhythmias Detected With an Implantable Cardiac Monitor in Patients After an Acute Myocardial Infarction. Current Treatment Options in Cardiovascular Medicine
CrossRef2
S. Mairesse, J. Blacher, M.-E. Safar. (2011) Mise au point sur les bêtabloquants pour les médecins vasculaires en 2012. Journal des Maladies Vasculaires
CrossRef3
Anant RC Patel, John R Hurst. (2011) Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Review of Respiratory Medicine 5:5, 647-662
CrossRef4
Mitja Lainscak, Matej Podbregar, Dragan Kovacic, Janez Rozman, Stephan von Haehling. (2011) Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respiratory Medicine 105, S44-S49
CrossRef5
Cristiana Vitale, Ilaria Spoletini, Maurizio Volterrani, Ferdinando Iellamo, Massimo Fini. (2011) Pattern of Use of β-Blockers in Older Patients with Stable Coronary Artery Disease. Drugs & Aging 28:9, 703-711
CrossRef6
Niels JC Ravensbergen, Michiel T Voute, Don Poldermans. (2011) Safety of perioperative β-blocker use: how do β-blockers compare in terms of side effects?. Expert Opinion on Drug Safety 10:4, 545-558
CrossRef7
R.P. Donahue, J.M. Dorn, S. Stranges, M. Swanson, K. Hovey, M. Trevisan. (2011) Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: Evidence of a sex difference? The Western New York experience. Nutrition, Metabolism and Cardiovascular Diseases 21:7, 504-511
CrossRef8
Ming-He Huang, Yewen Wu, Vincent Nguyen, Saurabh Rastogi, Bradley K. McConnell, Cori Wijaya, Barry F. Uretsky, Kian-Keong Poh, Huay-Cheem Tan, Kenichi Fujise. (2011) Heart Protection by Combination Therapy with Esmolol and Milrinone at Late-Ischemia and Early Reperfusion. Cardiovascular Drugs and Therapy 25:3, 223-232
CrossRef9
Nathaniel M. Hawkins, Mark C. Petrie, Michael R. MacDonald, Pardeep S. Jhund, Leonardo M. Fabbri, John Wikstrand, John J.V. McMurray. (2011) Heart Failure and Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology 57:21, 2127-2138
CrossRef10
Domenico Panuccio. (2011) BPCO e cardiopatia ischemica. Italian Journal of Medicine 5:1, 46-54
CrossRef11
Carlo Nozzoli, Giovanni Mathieu, Gianfranco Gensini. (2011) BPCO e scompenso cardiaco. Italian Journal of Medicine 5:1, 22-37
CrossRef12
Frans H Rutten. (2011) β-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease. Future Cardiology 7:1, 43-53
CrossRef13
Mary A. Burke, H. Peyton Young. 2011. Social Norms. , 311-338.
CrossRef14
Steffen Christensen, Martin Johansen, Else Tønnesen, Anders Larsson, Lars Pedersen, Stanley Lemeshow, Henrik Sørensen. (2011) Preadmission beta-blocker use and 30-day mortality among patients in intensive care: a cohort study. Critical Care 15:2, R87
CrossRef15
Thomas Kümler, Gunnar H Gislason, Lars Kober, Finn Gustafsson, Morten Schou, Christian Torp-Pedersen. (2011) Renal function at the time of a myocardial infarction maintains prognostic value for more than 10 years. BMC Cardiovascular Disorders 11:1, 37
CrossRef16
Giuseppe Musumeci, Roberta Rossini, Corrado Lettieri, Davide Capodanno, Michele Romano, Renato Rosiello, Giulio Guagliumi, Orazio Valsecchi, Antonello Gavazzi, Dominick J. Angiolillo. (2011) Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef17
Vesna Radovic. (2011) Use of beta blockers in various clinical states. Medicinski pregled 64:1-2, 55-60
CrossRef18
Susannah M. Bernheim, Yongfei Wang, Elizabeth H. Bradley, Frederick A. Masoudi, Saif S. Rathore, Joseph S. Ross, Elizabeth Drye, Harlan M. Krumholz. (2010) Who is missing from the measures? Trends in the proportion and treatment of patients potentially excluded from publicly reported quality measures. American Heart Journal 160:5, 943-950.e5
CrossRef19
Jeffrey J. Goldberger, Robert O. Bonow, Michael Cuffe, Alan Dyer, Yves Rosenberg, Robert O'Rourke, Prediman K. Shah, Sidney C. Smith. (2010) β-Blocker use following myocardial infarction: Low prevalence of evidence-based dosing. American Heart Journal 160:3, 435-442.e1
CrossRef20
Moutaz El-Kadri, Hala Sharaf-Dabbagh, David Ramsdale. (2010) REVIEW: Role of Antiischemic Agents in the Management of Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS). Cardiovascular Therapeuticsno-no
CrossRef21
Teemu L. Ahola, Ilkka M. Kantola, Pauli Puukka, Anna Kattainen, Timo Klaukka, Antti Reunanen, Antti M. Jula. (2010) Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult CHD patients in Finland: results from a large national database between 2000 and 2006. European Journal of Cardiovascular Prevention & Rehabilitation 17:4, 477-485
CrossRef22
B. Preckel, M. Poels, F. Wappler, W. Schlack, W. Buhre. (2010) Perioperative β-Rezeptoren-Blockade. Der Anaesthesist 59:7, 643-651
CrossRef23
CHUNG-WAH SIU, VINCENT PONG, MAN-HONG JIM, WEN-SHENG YUE, HEE-HWA HO, SHEUNG-WAI LI, CHU-PAK LAU, HUNG-FAT TSE. (2010) β-Blocker in Post-Myocardial Infarct Survivors with Preserved Left Ventricular Systolic Function. Pacing and Clinical Electrophysiology 33:6, 675-680
CrossRef24
(2010) Section 15: Management of Heart Failure in Special Populations. Journal of Cardiac Failure 16:6, e169-e175
CrossRef25
Dante Yeh, Monique Jones, Carl Schulman, Jagajan Karmacharya, Omaida C. Velazquez. (2010) Uninsured South Florida vascular surgery patients are less likely to receive optimal medical management than their insured counterparts. Journal of Vascular Surgery 51:4, S4-S8
CrossRef26
Jonathan G. Howlett, Robert S. McKelvie, Jeannine Costigan, Anique Ducharme, Estrellita Estrella-Holder, Justin A. Ezekowitz, Nadia Giannetti, Haissam Haddad, George A. Heckman, Anthony M. Herd, Debra Isaac, Simon Kouz, Kori Leblanc, Peter Liu, Elizabeth Mann, Gordon W. Moe, Eileen O’Meara, Miroslav Rajda, Samuel Siu, Paul Stolee, Elizabeth Swiggum, Shelley Zeiroth. (2010) The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Canadian Journal of Cardiology 26:4, 185-202
CrossRef27
Hadi A. R. Hadi, Mohammed Zubaid, Wael Al Mahmeed, Ayman A. El-Menyar, Mustafa Ridha, Alawi A. Alsheikh-Ali, Rajivir Singh, Nidal Assad, Khalid Al Habib, Jassim Al Suwaidi. (2010) Prevalence and Prognosis of Chronic Obstructive Pulmonary Disease Among 8167 Middle Eastern Patients With Acute Coronary Syndrome. Clinical Cardiology 33:4, 228-235
CrossRef28
Jonathan De Blois, Serge Simard, Dan Atar, Stefan Agewall. (2010) COPD Predicts Mortality in HF: The Norwegian Heart Failure Registry. Journal of Cardiac Failure 16:3, 225-229
CrossRef29
C. L. Chang, G. D. Mills, J. D. McLachlan, N. C. Karalus, R. J. Hancox. (2010) Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Internal Medicine Journal 40:3, 193-200
CrossRef30
Nicolas Roche, Antoine Rabbat, Mahmoud Zureik, Gérard Huchon. (2010) Chronic obstructive pulmonary disease exacerbations in emergency departments: predictors of outcome. Current Opinion in Pulmonary Medicine 16:2, 112-117
CrossRef31
Gordon W Moe, Jack Tu. (2010) Heart failure in the ethnic minorities. Current Opinion in Cardiology 25:2, 124-130
CrossRef32
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef33
Robert H. Neumayr, Paul J. Hauptman. (2009) β-Adrenergic receptor blockers and heart failure risk after myocardial infarction: A critical review. Current Heart Failure Reports 6:4, 220-228
CrossRef34
K. Candiotti, S. Sharma, R. Shankar. (2009) Obesity, obstructive sleep apnoea, and diabetes mellitus: anaesthetic implications. British Journal of Anaesthesia 103:Supplement 1, i23-i30
CrossRef35
Steinbeck, Gerhard, Andresen, Dietrich, Seidl, Karlheinz, Brachmann, Johannes, Hoffmann, Ellen, Wojciechowski, Dariusz, Kornacewicz-Jach, Zdzisława, Sredniawa, Beata, Lupkovics, Géza, Hofgärtner, Franz, Lubinski, Andrzej, Rosenqvist, Mårten, Habets, Alphonsus, Wegscheider, Karl, Senges, Jochen, . (2009) Defibrillator Implantation Early after Myocardial Infarction. New England Journal of Medicine 361:15, 1427-1436
Full Text36
Camila Manrique, Thomas D. Giles, Keith C. Ferdinand, James R. Sowers. (2009) Realities of Newer β-Blockers for the Management of Hypertension. The Journal of Clinical Hypertension 11:7, 369-375
CrossRef37
Wolfram Doehner, Stephan von Haehling, Stefan D. Anker, Mitja Lainscak. (2009) Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. Wiener klinische Wochenschrift 121:9-10, 293-296
CrossRef38
Simonetta Genovesi, Daniela M. Prata Pizzala, Massimo Pozzi, Laura Ratti, Maria Milanese, Federico Pieruzzi, Antonio Vincenti, Andrea Stella, Giuseppe Mancia, Marco Stramba
Badiale. (2009) QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clinical Science 116:12, 851-859
CrossRef39
E. Erdmann. (2009) Safety and tolerability of beta-blockers: prejudices and reality. European Heart Journal Supplements 11:Suppl A, A21-A25
CrossRef40
Maulik D. Majmudar, Christine Tompkins, Justin M. Bachmann, Roger S. Blumenthal, Joseph E. Marine. (2009) Effects of Lipid-Altering Therapies on Ventricular Arrhythmias and Sudden Cardiac Death. Cardiology in Review 17:2, 60-69
CrossRef41
Saravanan Balamuthusamy, Janos Molnar, Sasikanth Adigopula, Rohit Arora. (2009) Comparative Analysis of Beta-Blockers With Other Antihypertensive Agents on Cardiovascular Outcomes in Hypertensive Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis. American Journal of Therapeutics 16:2, 133-142
CrossRef42
Benjamin A. Olenchock, Gregg G. Fonarow, Wenqin Pan, Adrian Hernandez, Christopher P. Cannon. (2009) Current Use of Beta Blockers in Patients With Reactive Airway Disease Who Are Hospitalized With Acute Coronary Syndromes. The American Journal of Cardiology 103:3, 295-300
CrossRef43
N. M. Hawkins, Z. Huang, K. S. Pieper, S. D. Solomon, L. Kober, E. J. Velazquez, K. Swedberg, M. A. Pfeffer, J. J.V. McMurray, A. P. Maggioni, . (2009) Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure 11:3, 292-298
CrossRef44
Naoyuki Hirata, Noriaki Kanaya, Noriko Kamada, Saori Kimura, Akiyoshi Namiki. (2009) Differential Effects of Propofol and Sevoflurane on Ischemia-induced Ventricular Arrhythmias and Phosphorylated Connexin 43 Protein in Rats. Anesthesiology 110:1, 50-57
CrossRef45
Vesna Radovic. (2009) Studies of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease. Medicinski pregled 62:9-10, 450-455
CrossRef46
Nick Freemantle. (2008) Biostatistical aspects for the use of evidence based medicine in health technology assessment. The European Journal of Health Economics 9:S1, 31-43
CrossRef47
Laura M Gruen, Carl J Pepine. (2008) Ranolazine extended-release for chronic angina. Therapy 5:6, 807-815
CrossRef48
Daniel Kurnik, Chun Li, Gbenga G. Sofowora, Eitan A. Friedman, Mordechai Muszkat, Hong-Guang Xie, Paul A. Harris, Scott M. Williams, Usha B. Nair, Alastair J.J. Wood, C. Michael Stein. (2008) Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenetics and Genomics 18:10, 895-902
CrossRef49
G. König. (2008) Akut exazerbierte COPD. Der Pneumologe 5:5, 331-333
CrossRef50
Robina Matyal. (2008) Newly Appreciated Pathophysiology of Ischemic Heart Disease in Women Mandates Changes in Perioperative Management: A Core Review. Anesthesia & Analgesia 107:1, 37-50
CrossRef51
Robina Matyal, Feroze Mahmood, Peter Panzica, Frank Pomposelli, Kyung W. Park, Allen Hamden, Mark Schermerhorn, Philip Hess. (2008) Sex-Related Differences in Outcome After High-Risk Vascular Surgery After the Administration of β-Adrenergic–Blocking Drugs. Journal of Cardiothoracic and Vascular Anesthesia 22:3, 354-360
CrossRef52
Matthew A. Rank, James T. Li. (2008) β-Blocker prescription in elderly patients with asthma. Journal of Allergy and Clinical Immunology 121:4, 1061-1062
CrossRef53
M. Anselmino, K. Malmberg, J. Ohrvik, L. Ryden, . (2008) Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. European Journal of Cardiovascular Prevention & Rehabilitation 15:2, 216-223
CrossRef54
Juliana Jensen, Linda Hedin, Charlotte Widell, Petra Agnhom, Björn Andersson, Michael Fu. (2008) Characteristics of heart failure in the elderly — A hospital cohort registry-based study. International Journal of Cardiology 125:2, 191-196
CrossRef55
Jeffrey J. Goldberger, Robert O. Bonow, Michael Cuffe, Alan Dyer, Philip Greenland, Yves Rosenberg, Robert O'Rourke, Prediman K. Shah, Sidney Smith. (2008) Post–myocardial infarction β-blocker therapy: The bradycardia conundrum. Rationale and design for the Pacemaker & β-blocker therapy post-MI (PACE-MI) trial. American Heart Journal 155:3, 455-464
CrossRef56
S. Suttner, J. Boldt, K. Lang, J. Mayer, K. Röhm, S.N. Piper. (2008) Kontinuierliche β-Blockade mit Esmolol in Kombination mit Enoximon-Gabe. Der Anaesthesist 57:3, 231-241
CrossRef57
Shengmei Zhou, Alex Y. Tan, Offir Paz, Masahiro Ogawa, Chung-Chuan Chou, Hideki Hayashi, Motoki Nihei, Michael C. Fishbein, Lan S. Chen, Shien-Fong Lin, Peng-Sheng Chen. (2008) Antiarrhythmic effects of beta3-adrenergic receptor stimulation in a canine model of ventricular tachycardia. Heart Rhythm 5:2, 289-297
CrossRef58
Christine K Choy, Jo E Rodgers, Jean M Nappi, Stuart T Haines. (2008) Type 2 Diabetes Mellitus and Heart Failure. Pharmacotherapy 28:2, 170-192
CrossRef59
Shinichiro UEDA. (2008) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 39:5, 143-146
CrossRef60
David M. Lang. (2008) Do β-blockers really enhance the risk of anaphylaxis during immunotherapy?. Current Allergy and Asthma Reports 8:1, 37-44
CrossRef61
Søren Rasmussen, Steen Z. Abildstrom, Jeppe N. Rasmussen, Gunnar H. Gislason, Tina K. Schramm, Fredrik Folke, Lars Køber, Christian Torp-Pedersen, Mette Madsen. (2008) Hospital Variation in Use of Secondary Preventive Medicine After Discharge for First Acute Myocardial Infarction During 1995–2004. Medical Care 46:1, 70-77
CrossRef62
R. Ollivier, E. Donal, P. Delaval, J.-C. Daubert, P. Mabo. (2007) Prescription des bêtabloquants et bronchopneumopathie chronique obstructive. Annales de Cardiologie et d'Angéiologie 56:5, 231-236
CrossRef63
Ivan Goldberg, Michael A Adena. (2007) Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clinical & Experimental Ophthalmology 35:8, 700-705
CrossRef64
Stanley G. Rockson, Emil M. deGoma, Gregg C. Fonarow. (2007) Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes. Cardiovascular Drugs and Therapy 21:5, 375-388
CrossRef65
Lee, Thomas H., . (2007) Eulogy for a Quality Measure. New England Journal of Medicine 357:12, 1175-1177
Full Text66
R. Heine, B. Rau, R. Willenbrock. (2007) Präoperatives Management: Verbesserungsmöglichkeiten kardiopulmonaler Erkrankungen im Alter. Der Onkologe 13:9, 792-800
CrossRef67
Chadwick D. Miller, Matthew T. Roe, Jyotsna Mulgund, James W. Hoekstra, Renato Santos, Charles V. Pollack, E. Magnus Ohman, W. Brian Gibler, Eric D. Peterson. (2007) Impact of Acute Beta-Blocker Therapy for Patients with Non–ST-Segment Elevation Myocardial Infarction. The American Journal of Medicine 120:8, 685-692
CrossRef68
Kambiz Norozi, Jens Bahlmann, Björn Raab, Valentin Alpers, Jan O. Arnhold, Titus Kuehne, Katrin Klimes, Monika Zoege, Siegfried Geyer, Armin Wessel, Reiner Buchhorn. (2007) A prospective, randomized, double-blind, placebo controlled trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot. Cardiology in the Young 17:04, 372
CrossRef69
Sripal Bangalore, Franz H. Messerli, John B. Kostis, Carl J. Pepine. (2007) Cardiovascular Protection Using Beta-Blockers. Journal of the American College of Cardiology 50:7, 563-572
CrossRef70
Igor Bogdan Mrdovic, Lidija Zlatimir Savic, Jovan Petar Perunicic, Milika Risto Asanin, Ratko Milorad Lasica, Marinkovic Milutin Jelena, Mihailo Dragomir Matic, Zorana Mihailo Vasiljevic, Miodrag Caslav Ostojic. (2007) Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. American Heart Journal 154:1, 116-122
CrossRef71
Veikko Salomaa, Rauni P????kk??nen, Helena H??m??l??inen, Marja Niemi, Timo Klaukka. (2007) Use of secondary preventive medications after the first attack of acute coronary syndrome. European Journal of Cardiovascular Prevention & Rehabilitation 14:3, 386-391
CrossRef72
(2007) Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Española de Cardiología 60:5, 525.e1-525.e64
CrossRef73
Juan Tamargo, Ricardo Caballero, Ricardo Gómez, Lucía Núñez, Miguel Vaquero, Eva Delpón. (2007) Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacology & Therapeutics 114:1, 107-126
CrossRef74
Otto-Erich Brodde. (2007) β-adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn-Schmiedeberg's Archives of Pharmacology 374:5-6, 361-372
CrossRef75
LAN S. CHEN, SHENGMEI ZHOU, MICHAEL C. FISHBEIN, PENG-SHENG CHEN. (2007) New Perspectives on the Role of Autonomic Nervous System in the Genesis of Arrhythmias. Journal of Cardiovascular Electrophysiology 18:1, 123-127
CrossRef76
Thierry H. Le Jemtel, Margherita Padeletti, Sanja Jelic. (2007) Diagnostic and Therapeutic Challenges in Patients With Coexistent Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. Journal of the American College of Cardiology 49:2, 171-180
CrossRef77
Sanjai Sinha, Matthew Goldstein, Joan Penrod, Tsivia Hochman, Mohammad Kamran, Craig Tenner, Gabriela Cohen, Mark D. Schwartz. (2006) BRIEF REPORT: ?-Blocker Use Among Veterans with Systolic Heart Failure. Journal of General Internal Medicine 21:12, 1306-1309
CrossRef78
Felix K. Yam, Wendell S. Akers, Victor A. Ferraris, Kelly Smith, Chand Ramaiah, Phillip Camp, Jeremy D. Flynn. (2006) Interventions to improve guideline compliance following coronary artery bypass grafting. Surgery 140:4, 541-552
CrossRef79
Ramachandra R Sista, Kavita V Ernst, Euan A Ashley. (2006) Perioperative cardiac risk: pathophysiology, assessment and management. Expert Review of Cardiovascular Therapy 4:5, 731-743
CrossRef80
Sanjai Sinha, Matthew Goldstein, Joan Penrod, Tsivia Hochman, Mohammad Kamran, Craig Tenner, Gabriela Cohen, Mark D. Schwartz. (2006) BRIEF REPORT: β-Blocker Use Among Veterans with Systolic Heart Failure. Journal of General Internal Medicine 0:0, 060822080320008-???
CrossRef81
Saeid Behmanesh, Paschalis Tossios, Hossam Homedan, Khosro Hekmat, Martin Hellmich, Jochen Müller-Ehmsen, Robert H. G. Schwinger, Uwe Mehlhorn. (2006) Effect of prophylactic bisoprolol plus magnesium on the incidence of atrial fibrillation after coronary bypass surgery: results of a randomized controlled trial*. Current Medical Research and Opinion 22:8, 1443-1450
CrossRef82
Antoni Curós Abadal. (2006) De los ensayos clínicos a los registros: el registro PRIAMHO II. Revista Española de Cardiología 59:4, 301-304
CrossRef83
David M. Cutler. (2006) The Economics of Health System Payment. De Economist 154:1, 1-18
CrossRef84
Heart Failure Society of America. (2006) Section 15: Management of Heart Failure in Special Populations. Journal of Cardiac Failure 12:1, e115-e119
CrossRef85
Jean Ferrières, Jean-Pierre Cambou, Christelle Cantet, Louis Guize. (2006) Prognosis at 6 Months for Coronary and Cerebrovascular Patients: Impact of Antiplatelet Agents and Statins: Results from the Prevenir III Study. Cardiovascular Drugs and Therapy 20:1, 55-61
CrossRef86
Michael J Lipinski, George W Vetrovec. (2006) Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 6:5, 313-325
CrossRef87
Noritoshi Nagaya, Kenji Kangawa. (2006) Therapeutic Potential of Ghrelin in the Treatment of Heart Failure. Drugs 66:4, 439-448
CrossRef88
Takeshi Tsujino, Daizo Kawasaki, Tohru Masuyama. (2006) Left Ventricular Diastolic Dysfunction in Diabetic Patients. American Journal of Cardiovascular Drugs 6:4, 219-230
CrossRef89
Stephen Minor, Toshio Akiyama. (2006) Ventricular Arrhythmias in the Elderly. Journal of Arrhythmia 22:1, 19-30
CrossRef90
Keith C. Ferdinand, Elijah Sounders. (2006) Hypertension-Related Morbidity and Mortality in African Americans?Why We Need to Do Better. The Journal of Clinical Hypertension 8:s1, 21-30
CrossRef91
2006. Beta-adrenoceptor antagonists. , 452-478.
CrossRef92
Shengmei Zhou, Offir Paz, Ji-Min Cao, Kamlesh Asotra, Ning-Ning Chai, Charles Wang, Lan S. Chen, Michael C. Fishbein, Behrooz Sharifi, Peng-Sheng Chen. (2005) Differential β-adrenoceptor expression induced by nerve growth factor infusion into the canine right and left stellate ganglia. Heart Rhythm 2:12, 1347-1355
CrossRef93
Rachel M. Gilmore, Stephan J. Miller, Latha G. Stead. (2005) Severe Hypertension in the Emergency Department Patient. Emergency Medicine Clinics of North America 23:4, 1141-1158
CrossRef94
Shelley R Salpeter, Thomas M Ormiston, Edwin E Salpeter, Shelley R Salpeter. 2005. Cardioselective beta-blockers for chronic obstructive pulmonary disease. .
CrossRef95
I. A. Scott, P. B. Greenberg. (2005) Cautionary tales in the clinical interpretation of therapeutic trial reports. Internal Medicine Journal 35:10, 611-621
CrossRef96
M. M. Borst. (2005) Medikamentöse Therapie kardiovaskulärer Erkrankungen. Der Pneumologe 2:5, 324-332
CrossRef97
Crystal A. Gadegbeku, Janice P. Lea, Kenneth A. Jamerson. (2005) Update on Disparities in the Pathophysiology and Management of Hypertension: Focus on African Americans. Medical Clinics of North America 89:5, 921-933
CrossRef98
Tomie Kawada, Fujiko Masui, Asaki Tezuka, Takashi Ebisawa, Hiroyuki Kumagai, Mikio Nakazawa, Teruhiko Toyo-oka. (2005) A novel scheme of dystrophin disruption for the progression of advanced heart failure. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1751:1, 73-81
CrossRef99
David S. H. Bell. (2005) Optimizing treatment of diabetes and cardiovascular disease with combined α,β‐blockade. Current Medical Research and Opinion 21:8, 1191-1200
CrossRef100
Brent M. Egan, Jan Basile, Robert J. Chilton, Jerome D. Cohen. (2005) Cardioprotection: The Role of ?-Blocker Therapy. The Journal of Clinical Hypertension 7:7, 409-416
CrossRef101
Tomie Kawada, Fujiko Masui, Hiroyuki Kumagai, Miki Koshimizu, Mikio Nakazawa, Teruhiko Toyo-oka. (2005) A novel paradigm for therapeutic basis of advanced heart failure—assessment by gene therapy. Pharmacology & Therapeutics 107:1, 31-43
CrossRef102
Jalal K. Ghali. (2005) Beta-blockers in selected heart failure populations. Current Heart Failure Reports 2:2, 100-105
CrossRef103
Thomas F. Rehring, Brian G. Sandhoff, Ryan S. Stolcpart, John A. Merenich, H. Whitton Hollis. (2005) Atherosclerotic risk factor control in patients with peripheral arterial disease. Journal of Vascular Surgery 41:5, 816-822
CrossRef104
Amber E. Barnato, F Lee Lucas, Douglas Staiger, David E. Wennberg, Amitabh Chandra. (2005) Hospital-Level Racial Disparities in Acute Myocardial Infarction Treatment and Outcomes. Medical Care 43:4, 308-319
CrossRef105
R. Vanholder. (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrology Dialysis Transplantation 20:6, 1048-1056
CrossRef106
Ronina A. Covar, Beth A. Macomber, Stanley J. Szefler. (2005) Medications as asthma triggers. Immunology and Allergy Clinics of North America 25:1, 169-190
CrossRef107
(2005) Documento de Consenso de Expertos sobre bloqueadores de los receptores ß-adrenérgicos. Revista Española de Cardiología 58:1, 65-90
CrossRef108
Sergio Richter, Gabor Duray, Gerian Grönefeld, Carsten W Israel, Stefan H Hohnloser. (2005) Prevention of Sudden Cardiac Death. Circulation Journal 69:6, 625-629
CrossRef109
Margarite J Vale, Michael V Jelinek, James D Best. (2005) Impact of Coaching Patients on Coronary Risk Factors. Disease Management & Health Outcomes 13:4, 225-244
CrossRef110
H. Reinecke, G. Breithardt, H. Van Aken. (2005) Cardiological aspects in preoperative anaesthesiological evaluation: old heroes, new shadows. European Journal of Anaesthesiology 20:8, 595
CrossRef111
David C. Lee, Diana M. Pancu, Gary S. Rudolph, Andrew E. Sama. (2005) Age-associated time delays in the treatment of acute myocardial infarction with primary percutaneous transluminal coronary angioplasty. The American Journal of Emergency Medicine 23:1, 20-23
CrossRef112
J. Hultdin, A. M. Thogersen, J.-H. Jansson, T. K. Nilsson, L. Weinehall, G. Hallmans. (2004) Elevated plasma homocysteine: cause or consequence of myocardial infarction?. Journal of Internal Medicine 256:6, 491-498
CrossRef113
Keyur B. Shah, Stephen S. Gottlieb. (2004) Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. Current Heart Failure Reports 1:4, 161-167
CrossRef114
Li Wei, Robert Flynn, Gordon D. Murray, Thomas M. MacDonald. (2004) Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment?. Pharmacoepidemiology and Drug Safety 13:11, 761-766
CrossRef115
Christoph Maack, Michael B
hm. (2004) Klinischer Einsatz von Beta-Blockern bei kardiovaskul
CrossRef116
Rajiv Gupta, Yochai Birnbaum, Barry F. Uretsky. (2004) The renal patient with coronary artery disease. Journal of the American College of Cardiology 44:7, 1343-1353
CrossRef117
Adesuwa B. Olomu, Ralph E. Watson, Azfar-e-Alam Siddiqi, Francesca C. Dwamena, Barbara A. McIntosh, Peter Vasilenko, Joel Kupersmith, Margaret M. Holmes-Rovner, . (2004) Changes in Rates of Beta-blocker Use in Community Hospital Patients with Acute Myocardial Infarction. Journal of General Internal Medicine 19:10, 999-1004
CrossRef118
G.M. Lloyd, J.D. Newton, M.G.A. Norwood, S.C. Franks, M.J. Bown, R.D. Sayers. (2004) Patients with abdominal aortic aneurysm: Are we missing the opportunity for cardiovascular risk reduction?. Journal of Vascular Surgery 40:4, 691-697
CrossRef119
Anavekar, Nagesh S., McMurray, John J.V., Velazquez, Eric J., Solomon, Scott D., Kober, Lars, Rouleau, Jean-Lucien, White, Harvey D., Nordlander, Rolf, Maggioni, Aldo, Dickstein, Kenneth, Zelenkofske, Steven, Leimberger, Jeffrey D., Califf, Robert M., Pfeffer, Marc A., . (2004) Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. New England Journal of Medicine 351:13, 1285-1295
Full Text120
T Damci, H Kultursay, A Oguz, S Pehlivanoglu, L Tokgozoglu. (2004) Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey. Diabetes & Metabolism 30:4, 327-333
CrossRef121
Tseday E. Sirak, Sanja Jelic, Thierry H. Le Jemtel. (2004) Therapeutic Update: Non-Selective Beta- and Alpha-Adrenergic Blockade in Patients With Coexistent Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. Journal of the American College of Cardiology 44:3, 497-502
CrossRef122
Alex Adler, Barry H. Greenberg. (2004) Use of beta blockers in patients with post-MI left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine 6:4, 335-343
CrossRef123
Hamik A. Martirosyan, Eric P. Brass, Rajnish Mehrotra, Sharon G. Adler. (2004) Differential management of cardiovascular disease in ESRD by nephrologists and cardiologists1 1Members of the Cardio-Renal Responder Group and the Validation Cohort are listed in Appendix I.. American Journal of Kidney Diseases 44:2, 309-321
CrossRef124
J. M. Perschbacher, G. S. Reeder, S. J. Jacobsen, S. A. Weston, J. M. Killian, A. Slobodova, V. L. Roger. (2004) Evidence-Based Therapies for Myocardial Infarction: Secular Trends and Determinants of Practice in the Community. Mayo Clinic Proceedings 79:8, 983-991
CrossRef125
Andrea Di Lenarda, Gastone Sabbadini, Michele Moretti, Gianfranco Sinagra. (2004) Long-term oral carvedilol in chronic heart failure. Expert Opinion on Pharmacotherapy 5:6, 1359-1372
CrossRef126
J.-F. Rouland. (2004) Le traitement médical initial : bêtabloquants ou prostaglandines ?. Journal Français d'Ophtalmologie 27:6, 716-717
CrossRef127
Mori J. Krantz, Edward P. Havranek, Philip S. Mehler, Deborah K. Haynes, Carlin S. Long. (2004) Impact of a Cardiac Risk Reduction Program in Vulnerable Patients Hospitalized with Coronary Artery Disease. Pharmacotherapy 24:6, 768-775
CrossRef128
Brian Schwartz, Marian J. Vermeulen, Chris Idestrup, Partha Datta. (2004) Clinical Variables Associated with Mortality in Out-of-hospital Patients with Hemodynamically Significant Bradycardia. Academic Emergency Medicine 11:6, 656-661
CrossRef129
P.Michael Ho, Frederick A Masoudi, Eric D Peterson, Gary K Grunwald, Anne E Sales, Karl E Hammermeister, John S Rumsfeld. (2004) Cardiology management improves secondary prevention measures among patients with coronary artery disease. Journal of the American College of Cardiology 43:9, 1517-1523
CrossRef130
Steven J Kernis, Kishore J Harjai, Gregg W Stone, Lorelei L Grines, Judith A Boura, William W O'Neill, Cindy L Grines. (2004) Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty?. Journal of the American College of Cardiology 43:10, 1773-1779
CrossRef131
Brian Schwartz, Marian J. Vermeulen, Chris Idestrup, Partha Datta. (2004) Clinical Variables Associated with Mortality in Out-of-hospital Patients with Hemodynamically Significant Bradycardia. Academic Emergency Medicine 11:5, 656-661
CrossRef132
Domenic A. Sica, Joel M. Neutel, Michael A. Weber, Neil Manowitz. (2004) The Antihypertensive Efficacy and Safety of a Chronotherapeutic Formulation of Propranolol in Patients With Hypertension. The Journal of Clinical Hypertension 6:5, 231-241
CrossRef133
Gail M. Powell-Cope, Stephen Luther, Britta Neugaard, John Vara, Audrey Nelson. (2004) Provider-perceived barriers and facilitators for ischaemic heart disease (IHD) guideline adherence. Journal of Evaluation in Clinical Practice 10:2, 227-239
CrossRef134
Brian NC Prichard, Patrick Vallance. (2004) ESH/ESC guidelines. Journal of Hypertension 22:4, 859-861
CrossRef135
Clyde W. Yancy. (2004) Improving Outcomes in the Post-Myocardial Infarction Setting. The Journal of Clinical Hypertension 6:s4, 34-41
CrossRef136
Duminda N Wijeysundera, W.Scott Beattie, Vivek Rao, Joan Ivanov, Keyvan Karkouti. (2004) Calcium antagonists are associated with reduced mortality after cardiac surgery: a propensity analysis. The Journal of Thoracic and Cardiovascular Surgery 127:3, 755-762
CrossRef137
Dario DiFrancesco, John A Camm. (2004) Heart Rate Lowering by Specific and Selective If Current Inhibition with Ivabradine. Drugs 64:16, 1757-1765
CrossRef138
Rosemary S. Bubien, Elizabeth A. Ching, G. Neal Kay. (2004) Cardiac Defibrillation and Resynchronization Therapies. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 15:3, 340-361
CrossRef139
Gregg C. Fonarow, William T. Abraham, Mihai Gheorghiade, Christopher P. Cannon, Jonathan D. Sackner-Bernstein, James E. Udelson, Marvin A. Konstam. (2003) Role of β-Blocker Therapy in the Postmyocardial Infarction Patient With and Without Left Ventricular Dysfunction Consensus Guideline. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 2:4, 239-246
CrossRef140
D. B. Coursin, M. J. Murray. (2003) How Sweet is Euglycemia in Critically Ill Patients?. Mayo Clinic Proceedings 78:12, 1460-1462
CrossRef141
David Johnson, Yan Jin, Hude Quan, Bibiana Cujec. (2003) Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. Journal of the American College of Cardiology 42:8, 1438-1445
CrossRef142
S.R Salpeter, T.M Ormiston, E.E Salpeter, P.J Poole, C.J Cates. (2003) Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respiratory Medicine 97:10, 1094-1101
CrossRef143
Mori J. Krantz. (2003) Secondary Prevention of Coronary Artery Disease: Combining the Evidence. Primary Care Case Reviews 6:3, 110-120
CrossRef144
Antje Habicht, Bruno Watschinger. (2003) Sympathische Überaktivität und Niere. Wiener Klinische Wochenschrift 115:17-18, 634-640
CrossRef145
H. Reinecke, G. Breithardt, H. Van Aken. (2003) Cardiological aspects in preoperative anaesthesiological evaluation: old heroes, new shadows. European Journal of Anaesthesiology 20:8, 595-599
CrossRef146
Luis M Ruilope, Julián Segura, Carlos Campo, José L Rodicio. (2003) Renal participation in cardiovascular risk inessential hypertension. Expert Review of Cardiovascular Therapy 1:2, 309-315
CrossRef147
Robert L. Scott. (2003) Is Heart Failure in African Americans a Distinct Entity?. Congestive Heart Failure 9:4, 193-196
CrossRef148
Noritoshi Nagaya, Kenji Kangawa. (2003) Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. Regulatory Peptides 114:2-3, 71-77
CrossRef149
C.D. Karkos. (2003) What is Appropriate Coronary Assessment Prior to Abdominal Aortic Surgery?. European Journal of Vascular and Endovascular Surgery 25:6, 487-492
CrossRef150
Jacques Amar, Bernard Chamontin, Nathalie Genes, Christelle Cantet, Michel Salvador, Jean Pierre Cambou. (2003) Why is hypertension so frequently uncontrolled in secondary prevention?. Journal of Hypertension 21:6, 1199-1205
CrossRef151
S. L. Nuttall, H. C. Routledge, M. J. Kendall. (2003) A comparison of the beta1-selectivity of three beta1-selective beta-blockers. Journal of Clinical Pharmacy and Therapeutics 28:3, 179-186
CrossRef152
Susan K. Maue, James H. Jackson, Bruce A. Weiss, Marc L. Rivo, Vishu Jhaveri, Barbara Lennert. (2003) The Hypertension Management Program: Identifying Opportunities for Improvement. The Journal of Clinical Hypertension 5:3, 33-40
CrossRef153
J. Herbert Patterson, Jo E. Rodgers. (2003) Expanding Role of β-Blockade in the Management of Chronic Heart Failure. Pharmacotherapy 23:4, 451-459
CrossRef154
Christine M. Logar, Charles A. Herzog, Srinivasan Beddhu. (2003) Diagnosis and Therapy of Coronary Artery Disease in Renal Failure, End-Stage Renal Disease, and Renal Transplant Populations. The American Journal of the Medical Sciences 325:4, 214-227
CrossRef155
(2003) Atrial Fibrillation — Rate versus Rhythm Control. New England Journal of Medicine 348:13, 1284-1286
Full Text156
Sanjay Kumar, Roger J C Hall. (2003) Drug Treatment of Stable Angina Pectoris in the Elderly. Drugs & Aging 20:11, 805-815
CrossRef157
Mauro Di Bari, Niccol?? Marchionni, Marco Pahor. (2003) ??-Blockers after Acute Myocardial Infarction in Elderly Patients with Diabetes Mellitus. Drugs & Aging 20:1, 13-22
CrossRef158
Ian A Scott. (2003) Determinants of Quality of In-Hospital Care for Patients with Acute Coronary Syndromes. Disease Management & Health Outcomes 11:12, 801-816
CrossRef159
Britta I. Neugaard, Robert G. Zoble, Jason W. Beckstead, Audrey L. Nelson. (2003) Ischaemic heart disease guidelines and cardiac medications use in veterans administration hospitals. Clinical Governance: An International Journal 8:4, 300-307
CrossRef160
Richard I. Levin, Karen L. Koenig, Michael P. Corder, Narinder P. Bhalla, Barry P. Rosenzweig, Phoebe A. Recht. (2002) Risk Stratification and Prevention in Chronic Coronary Artery Disease: Use of a Novel Prognostic and Computer-Based Clinical Decision Support System in a Large Primary Managed-Care Group Practice. Disease Management 5:4, 197-213
CrossRef161
Jessica E. Burjorjee, Brian Milne. (2002) Propofol for electrical storm; a case report of cardioversion and suppression of ventricular tachycardia by propofol. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 49:9, 973-977
CrossRef162
Stephen A Geraci, Constance K Haan. (2002) Effect of beta blockers after coronary artery bypass in postinfarct patients: what can we learn from available literature?. The Annals of Thoracic Surgery 74:5, 1727-1732
CrossRef163
Javed Butler, Patrick G Arbogast, Rhonda BeLue, James Daugherty, Manoj K Jain, Wayne A Ray, Marie R Griffin. (2002) Outpatient adherence to beta-blocker therapy after acute myocardial infarction. Journal of the American College of Cardiology 40:9, 1589-1595
CrossRef164
P.- G. Chassot, A. Delabays, D. R. Spahn. (2002) Preoperative evaluation of patients with, or at risk of, coronary artery disease undergoing non-cardiac surgery. British Journal of Anaesthesia 89:5, 747-759
CrossRef165
Shelley R Salpeter, Thomas M Ormiston, Edwin E Salpeter, Richard Wood-Baker, Shelley R Salpeter. 2002. Cardioselective beta-blockers for reversible airway disease. .
CrossRef166
Audrey H Wu, Lori Parsons, Nathan R Every, Eric R Bates. (2002) Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. Journal of the American College of Cardiology 40:8, 1389-1394
CrossRef167
Stefan W. Suttner, Swen N. Piper, Joachim Boldt. (2002) The heart in the elderly critically ill patient. Current Opinion in Critical Care 8:5, 389-394
CrossRef168
Johan De Sutter, Vida Firsovaite, Rene Tavernier. (2002) Prevention of Sudden Death in Patients With Coronary Artery Disease: Do Lipid-Lowering Drugs Play a Role?. Preventive Cardiology 5:4, 177-182
CrossRef169
Richard Levy. (2002) Costs and Benefits of Pharmaceuticals: The Value Equation for Older Americans. Care Management Journals 3:3, 135-143
CrossRef170
Steven P Marso. (2002) Optimizing the diabetic formulary: beyond aspirin and insulin. Journal of the American College of Cardiology 40:4, 652-661
CrossRef171
M. J. Landray, V. Toescu, M. J. Kendall. (2002) The cardioprotective role of beta-blockers in patients with diabetes mellitus. Journal of Clinical Pharmacy and Therapeutics 27:4, 233-242
CrossRef172
D WALLER. (2002) Management Following Myocardial Infarction. Medicine 30:4, 76-80
CrossRef173
Martin St. John Sutton, Victor A. Ferrari. (2002) Prevention of left ventricular remodeling after myocardial infarction. Current Treatment Options in Cardiovascular Medicine 4:2, 97-108
CrossRef174
Ida Sim, Gillian D. Sanders, Kathryn M. McDonald. (2002) Evidence-based Practice for Mere Mortals. The Role of Informatics and Health Services Research. Journal of General Internal Medicine 17:4, 302-308
CrossRef175
Francesco Cosentino, Sandro Bonetti, Rudolf Rehorik, Masato Eto, Gabriele Werner-Felmayer, Massimo Volpe, Thomas F. Lüscher. (2002) Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic β1-selective receptor blockade. Journal of Hypertension 20:3, 421-428
CrossRef176
Volker K??hlkamp, Ralph Bosch, Christian Mewis, Ludger Seipel. (2002) Use of ??-Blockers in Atrial Fibrillation. American Journal of Cardiovascular Drugs 2:1, 37-42
CrossRef177
S. Mitra, K. Findley, D. Frohnapple, J. L. Mehta. (2002) Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital. Clinical Cardiology 25:1, 16-18
CrossRef178
C. Venkata Ram. (2002) Antihypertensive Drugs. American Journal of Cardiovascular Drugs 2:2, 77-89
CrossRef179
Amy Chorzempa, Patricia Tabloski. (2002) Post myocardial infarction treatment in the older adult. Dimensions of Critical Care Nursing 21:1, 20-25
CrossRef180
Kinji Ishikawa, Akio Kimura, Takaaki Taniwa, Toshihiko Takenaka, Takahiro Hayashi, Ken Kanamasa, on behalf of the Secondary Preventi. (2002) Modification of Treatment Strategies Over a Period of 14 Years Has Markedly Reduced Cardiac Events Among Post-Myocardial Infarction Patients. Circulation Journal 66:10, 881-885
CrossRef181
Luis M. Ruilope, Dirk J. van Veldhuisen, Eberhard Ritz, Thomas F. Luscher. (2001) Renal function: the Cinderella of cardiovascular risk profile. Journal of the American College of Cardiology 38:7, 1782-1787
CrossRef182
E. R. Christ, P. V. Carroll, E. Albany, A. M. Umpleby, P. J. Lumb, A. S. Wierzbicki, H. L. Simpson, P. H. Sönksen, D. L. Russell-Jones. (2001) Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. Clinical Endocrinology 55:6, 777-787
CrossRef183
Catarina I. Kiefe. (2001) Processes and Outcomes in Acute Myocardial Infarction. How Technical Should We Get?. Journal of General Internal Medicine 16:12, 868-869
CrossRef184
Huikuri, Heikki V., Castellanos, Agustin, Myerburg, Robert J., . (2001) Sudden Death Due to Cardiac Arrhythmias. New England Journal of Medicine 345:20, 1473-1482
Full Text185
Donald D. Tresch, Haritha R. Alla. (2001) Diagnosis and Management of Myocardial Ischemia (Angina) in the Elderly Patient. The American Journal of Geriatric Cardiology 10:6, 337-344
CrossRef186
Kewal K. Talwar, Nitish Naik, Rajnish Juneja. (2001) Are drugs and catheter ablation effective for treating ventricular arrhythmias in populations that cannot afford implantable cardioverter defibrillators?. Current Cardiology Reports 3:6, 459-466
CrossRef187
J. Auer, R. Berent, B. Eber. (2001) Pathophysiologische und therapeutische Aspekte des linksventrikularen "Remodelings" in der Postinfarktphase. Acta Medica Austriaca 28:5, 117-122
CrossRef188
Chester B. Good. (2001) Topical beta-blockers in patients with co-existing conditions: is this a cause for concern?. Pharmacoepidemiology and Drug Safety 10:6, 509-510
CrossRef189
Jayant A. Talwalkar, Patrick S. Kamath. (2001) Screening for esophageal varices among patients with cirrhosis of the liver. The American Journal of Gastroenterology 96:10, 3039-3040
CrossRef190
S. J. Nicholls, P. McElduff, A. J. Dobson, K. D. Jamrozik, M. S. T. Hobbs, J. W. Leitch. (2001) Underuse of beta-blockers following myocardial infarction: a tale of two cities. Internal Medicine Journal 31:7, 391-396
CrossRef191
Donna S. Hanes, Matthew R. Weir. (2001) The ? Blockers: Are They as Protective in Hypertension as in other Cardiovascular Conditions?. The Journal of Clinical Hypertension 3:4, 236-243
CrossRef192
Jersey Chen, Martha J Radford, Yun Wang, Thomas A Marciniak, Harlan M Krumholz. (2001) Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. Journal of the American College of Cardiology 37:7, 1950-1956
CrossRef193
D. Elsner. (2001) How to diagnose and treat coronary artery disease in the uraemic patient: an update. Nephrology Dialysis Transplantation 16:6, 1103-1108
CrossRef194
(2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. The Lancet 357:9266, 1385-1390
CrossRef195
S Schroeder. (2001) Self-rated health and clinical status after PTCA: results of a 4-year follow-up in 500 patients. European Journal of Internal Medicine 12:2, 101-106
CrossRef196
Jeffrey M Bloom. (2001) Pravastatin and coronary heart disease. The Lancet 357:9261, 1040
CrossRef197
JOEL B. BRAUNSTEIN, ALAN CHENG, CAROLE FAKHRY, CAITLIN M. NASS, CAMILLE VIGILANCE, ROGER S. BLUMENTHAL. (2001) ABCs of Cardiovascular Disease Risk Management. Cardiology in Review 9:2, 96-105
CrossRef198
Kenneth J. Tuman. (2001) Perioperative Cardiovascular Risk: Assessment and Management. Anesthesia and Analgesia106-112
CrossRef199
Sara Jones Reeder, Rosemary L. Hoffmann. (2001) Beta-blocker therapy for hypertension. Dimensions of Critical Care Nursing 20:2, 2-9
CrossRef200
Amy Chorzempa, Patricia Tabloski. (2001) Post Myocardial Infarction Treatment in the Older Adult. The Nurse Practitioner36-49
CrossRef201
Joseph T. Hanlon, Kenneth E. Schmader, Christine M. Ruby, Morris Weinberger. (2001) Suboptimal Prescribing in Older Inpatients and Outpatients. Journal of the American Geriatrics Society 49:2, 200-209
CrossRef202
N. Younis, P. Burnham, A. Patwala, P J. Weston, J P. Vora. (2001) Beta blocker prescribing differences in patients with and without diabetes following a first myocardial infarction. Diabetic Medicine 18:2, 159-161
CrossRef203
K.K. Talwar, N. Naik. (2001) Etiology and Management of Sustained Ventricular Tachycardia. American Journal of Cardiovascular Drugs 1:3, 179-192
CrossRef204
Brad G. Angeja, C. Michael Gibson, Richard Chin, John G. Canto, Hal V. Barron. (2001) Use of Reperfusion Therapies in Elderly Patients with Acute Myocardial Infarction. Drugs & Aging 18:8, 587-596
CrossRef205
Fidelma Dunne, Martin J. Kendall, Una Martin. (2001) ??-Blockers in the Management of Hypertension in Patients with Type 2 Diabetes Mellitus. Drugs 61:4, 429-435
CrossRef206
Robert A. Cina, James B. Froehlich, Allen D. Hamdan. (2001) Perioperative β-Blockade to Reduce Cardiac Morbidity in Noncardiac Surgery. International Anesthesiology Clinics 39:4, 93-104
CrossRef207
Giuditta Angelini, Jonathan T. Ketzler, Douglas B. Coursin. (2001) Perioperative Care of the Diabetic Patient. ASA Refresher Courses in Anesthesiology 29:1, 1-9
CrossRef208
S. L. Nuttall, N. J. Langford, M. J. Kendall. (2000) Beta-blockers in heart failure. 1. Clinical evidence. Journal of Clinical Pharmacy and Therapeutics 25:6, 395-398
CrossRef209
Pekka Porela, Hans Helenius, Kari Pulkki, Olli Peltola, Kai-Petri Hänninen, Kim Pettersson, Marika Wacker, Liisa-Maria Voipio-Pulkki. (2000) Cardiac decompensation during an ischemic event weakens the predictive power of myocardial injury markers. Clinica Chimica Acta 302:1-2, 133-144
CrossRef210
Lionel H Opie. (2000) First line drugs in chronic stable effort angina—the case for newer, longer-acting calcium channel blocking agents. Journal of the American College of Cardiology 36:6, 1967-1971
CrossRef211
Garfield A Drummond. (2000) Diltiazem after thrombolysis. The Lancet 356:9241, 1604-1605
CrossRef212
Jeffrey J Goldberger, Suresh Neelagaru. (2000) Therapeutic developments in sudden cardiac death. Expert Opinion on Investigational Drugs 9:11, 2543-2554
CrossRef213
(2000) Observational Studies and Randomized Trials. New England Journal of Medicine 343:16, 1194-1197
Full Text214
Wayne L. Miller, R. Scott Wright, Joseph P. Grill, Stephen L. Kopecky. (2000) Improved survival after acute myocardial infarction in patients with advanced killip class. Clinical Cardiology 23:10, 751-758
CrossRef215
Peter A McCullough, Sandeep S Soman, Shalin S Shah, Stephen T Smith, Keisha R Marks, Jerry Yee, Steven Borzak. (2000) Risks associated with renal dysfunction in patients in the coronary care unit. Journal of the American College of Cardiology 36:3, 679-684
CrossRef216
Stein Ørn, Kenneth Dickstein. (2000) Pharmacotherapy following myocardial infarction - a review of current treatment practices. Expert Opinion on Pharmacotherapy 1:6, 1105-1116
CrossRef217
(2000) Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus. New England Journal of Medicine 343:8, 580-581
Full Text218
O.A. Obel. (2000) Revisiting established medical options — antiarrhythmic drugs and β-blocker combinations. Resuscitation 45:3, S7-S10
CrossRef219
Paula A Rochon, Jack V Tu, Geoffrey M Anderson, Jerry H Gurwitz, Jocalyn P Clark, Paula Lau, John Paul Szalai, Kathy Sykora, C David Naylor. (2000) Rate of heart failure and 1-year survival for older people receiving low-dose β-blocker therapy after myocardial infarction. The Lancet 356:9230, 639-644
CrossRef220
V. Piriou, A. Aouifi, J. J. Lehot. (2000) Intérêt des bêta-bloquants en médecine périopératoire. Deuxième partie: indications thérapeutiques. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 47:7, 664-672
CrossRef221
Volker Kühlkamp, Alexander Schirdewan, Karl Stangl, Michael Homberg, Matthias Ploch, Otto A Beck. (2000) Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. Journal of the American College of Cardiology 36:1, 139-146
CrossRef222
Martinez-Rubio, Fahlin, Llanos. (2000) Role of neuropeptides in heart failure: preliminary information or knowledge?. European Journal of Clinical Investigation 30:7, 561-562
CrossRef223
William R. Hogan, G. Daniel Martich. (2000) Soundbites and snapshots: What is a day?. Critical Care Medicine 28:6, 2169
CrossRef224
McNamara, Peterson, Friesen. (2000) Changes in the management of acute myocardial infarction in Southern Tasmania. Journal of Clinical Pharmacy and Therapeutics 25:2, 111-118
CrossRef225
Ian A Scott, Margo L Eyeson-Annan, Sue L Huxley, Malcolm J West. (2000) Optimising care of acute myocardial infarction: Results of a regional quality improvement project. Journal of Quality in Clinical Practice 20:1, 12-19
CrossRef226
Helfried Metzler. (2000) Perioperative myocardial cell injury in noncardiac surgery - time for an optimistic view?. Current Opinion in Anaesthesiology 13:1, 1-3
CrossRef227
M. Bilal Murad, Timothy D. Henry. (2000) Unstable angina. Current Treatment Options in Cardiovascular Medicine 2:1, 37-53
CrossRef228
. (2000) bètablokkeerdersBètablokkeerders na een myocardinfarctmyocardinfarct; ook bij een ‘contra-indicatiecontra-indicatie’?. Medisch-Farmaceutische Mededelingen 38:2, 27-28
CrossRef229
Ross T. Tsuyuki, Finlay A. McAlister, Koon K. Teo. (2000) ??-Blockers For Congestive Heart Failure. Drugs & Aging 16:1, 1-7
CrossRef230
Gerard W. Graham, Byron P. Unger, Douglas B. Coursin. (2000) Perioperative Management of Selected Endocrine Disorders. International Anesthesiology Clinics 38:4, 31-67
CrossRef231
Edward D Frohlich. (1999) The necessity for recognition and treatment of patients with “mild” hypertension. Journal of the American College of Cardiology 34:5, 1369-1377
CrossRef232
Jersey Chen, Thomas A Marciniak, Martha J Radford, Yun Wang, Harlan M Krumholz. (1999) Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Journal of the American College of Cardiology 34:5, 1388-1394
CrossRef233
Michael O???Leary, Michael Davis, David Bihari. (1999) Myocardial protection in the intensive care unit. Current Opinion in Critical Care 5:5, 400-407
CrossRef234
Thomas A. Hodgson, Alan J. Cohen. (1999) Medical Care Expenditures for Selected Circulatory Diseases. Medical Care 37:10, 994-1012
CrossRef235
Thomas J Ryan, Elliott M Antman, Neil H Brooks, Robert M Califf, L.David Hillis, Loren F Hiratzka, Elliot Rapaport, Barbara Riegel, Richard O Russell, Earl E Smith, W.Douglas Weaver, Raymond J Gibbons, Joseph S Alpert, Kim A Eagle, Timothy J Gardner, Arthur Garson, Gabriel Gregoratos, Richard O Russell, Thomas J Ryan, Sidney C Smith. (1999) 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. Journal of the American College of Cardiology 34:3, 890-911
CrossRef236
Joanne Gilbert, Lucia Lazio. (1999) Managing Congestive Heart Failure With Thoracic Electrical Bioimpedance. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 10:3, 400-405
CrossRef237
Mohammad J. Tafreshi, Ann B. Weinacker. (1999) β-Adrenergic-Blocking Agents in Bronchospastic Diseases: A Therapeutic Dilemma. Pharmacotherapy 19:8, 974-978
CrossRef238
Michael A. Blazing, Christopher M. O’Connor. (1999) Evidence supporting secondary prevention strategies. Current Opinion in Cardiology 14:4, 303-309
CrossRef239
M. J. Kendall, V. Toescu, S. L. Nuttall. (1999) Angina and its treatment. Journal of Clinical Pharmacy and Therapeutics 24:3, 171-179
CrossRef240
Kate L. Lapane, Marilyn M. Barbour, Anne Van Haaren, Giovanni Gambassi. (1999) Antiischemic Therapy in Patients with Coronary Heart Disease Living in Long-term Care. Pharmacotherapy 19:5, 627-634
CrossRef241
(1999) Pravastatin and Coronary Heart Disease. New England Journal of Medicine 340:14, 1115-1117
Full Text242
Kenneth J. Tuman, Robert J. McCarthy. (1999) Individualizing beta-Adrenergic Blocker Therapy. Anesthesia & Analgesia 88:3, 475-476
CrossRef243
Christopher E. Cannon, Sidney C. Smith. (1999) Current therapies for secondary prevention after myocardial infarction. Current Opinion in Cardiology 14:2, 155
CrossRef244
Gary L. Schwartz, Sheldon G. Sheps. (1999) A review of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Current Opinion in Cardiology 14:2, 161
CrossRef245
(1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet 353:9146, 9-13
CrossRef246
(1998) Beta-Blockers after Myocardial Infarction. New England Journal of Medicine 339:27, 2022-2023
Full Text247
Radford, Martha J., , Krumholz, Harlan M., . (1998) Beta-Blockers after Myocardial Infarction — For Few Patients, or Many?. New England Journal of Medicine 339:8, 551-553
Full Text
- Letters
